Six-Week Open-Label Reboxetine Treatment in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder
This open-label study assessed the effectiveness of reboxetine, a selective norepinephrine reuptake inhibitor, in children and adolescents with attention-deficit/hyperactivity disorder (ADHD) resistant to a previous methylphenidate trial. Thirty-one child and adolescent outpatients, aged 8 to 18 (me...
Gespeichert in:
| Veröffentlicht in: | Journal of the American Academy of Child and Adolescent Psychiatry 2005-05, Vol.44 (5), p.428-433 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 433 |
|---|---|
| container_issue | 5 |
| container_start_page | 428 |
| container_title | Journal of the American Academy of Child and Adolescent Psychiatry |
| container_volume | 44 |
| creator | Ratner, Sharon Laor, Nathaniel Bronstein, Yifat Weizman, Abraham Toren, Paz |
| description | This open-label study assessed the effectiveness of reboxetine, a selective norepinephrine reuptake inhibitor, in children and adolescents with attention-deficit/hyperactivity disorder (ADHD) resistant to a previous methylphenidate trial.
Thirty-one child and adolescent outpatients, aged 8 to 18 (mean age, 11.7; SD = 2.87) years, diagnosed with ADHD were enrolled in a 6-week open-label study. Assessments included rater-administered scales (DSM-IV ADHD Scale; Clinical Global Impressions Scale), parent-administered scales (the Abbreviated Conners Rating Scale), and self-administered-scales for the evaluation of depressive (Children's Depression Inventory) and anxiety (the Revised Children's Manifest Anxiety Scale) symptoms. Reboxetine was initiated and maintained at a dose of 4 mg/day.
A significant decrease in ADHD symptoms, on all scales measured, was noted. Adverse effects were relatively mild and transient. The most common adverse effects were drowsiness/sedation and gastrointestinal complaints.
The results of the current open-label study suggest the effectiveness of reboxetine in the treatment of ADHD in methylphenidate-resistant children and adolescents. Double-blind, placebo-, and active comparator-controlled studies are indicated to rigorously test the efficacy of reboxetine in ADHD. |
| doi_str_mv | 10.1097/01.chi.0000155327.30017.8c |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_212646403</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><ericid>EJ697113</ericid><els_id>S0890856709615033</els_id><sourcerecordid>829312411</sourcerecordid><originalsourceid>FETCH-LOGICAL-c456t-c8001d04df4d9d32fcb36edf221a62d63eaeeab40cdb63a5d190cf8b6d816c333</originalsourceid><addsrcrecordid>eNqNkF1v0zAUhi0EYmXwDxCyJnGZzI4Tx-WuagcDVZoEQ7u0nOMT1SN1iu1O67_HpRG9xTe29T7nQw8hV5yVnM3ba8ZL2LiS5cObRlRtKfKrLRW8IDPeVG3R1Fy9JDOm5qxQjWwvyJsYH498q9RrcsEbVYtW1jMSfrjn4gHxF73boS_WpsOBfsdufMbkPNL7gCZt0SfqPF1u3GADemq8pQs7DhghR5E-uLShi5Tyx42-WGHvwKXr28MOg4Hknlw60JWLY7AY3pJXvRkivpvuS_Lz88398rZY3335ulysC6gbmQpQeV3LatvXdm5F1UMnJNq-qriRlZUCDaLpaga2k8I0ls8Z9KqTVnEJQohLcnXquwvj7z3GpB_HffB5pK54JWtZsyP06QRBGGMM2OtdcFsTDpozfbStGdfZtj7b1n9tawW5-MM0Yd9t0Z5LJ70Z-DgBJoIZ-mA8uHjmZJs34Txz708cBgf_4ptvct7mNMerKc66nhwGHcGhB7QuICRtR_c_6_4BXTip3Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>212646403</pqid></control><display><type>article</type><title>Six-Week Open-Label Reboxetine Treatment in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><source>Applied Social Sciences Index & Abstracts (ASSIA)</source><creator>Ratner, Sharon ; Laor, Nathaniel ; Bronstein, Yifat ; Weizman, Abraham ; Toren, Paz</creator><creatorcontrib>Ratner, Sharon ; Laor, Nathaniel ; Bronstein, Yifat ; Weizman, Abraham ; Toren, Paz</creatorcontrib><description>This open-label study assessed the effectiveness of reboxetine, a selective norepinephrine reuptake inhibitor, in children and adolescents with attention-deficit/hyperactivity disorder (ADHD) resistant to a previous methylphenidate trial.
Thirty-one child and adolescent outpatients, aged 8 to 18 (mean age, 11.7; SD = 2.87) years, diagnosed with ADHD were enrolled in a 6-week open-label study. Assessments included rater-administered scales (DSM-IV ADHD Scale; Clinical Global Impressions Scale), parent-administered scales (the Abbreviated Conners Rating Scale), and self-administered-scales for the evaluation of depressive (Children's Depression Inventory) and anxiety (the Revised Children's Manifest Anxiety Scale) symptoms. Reboxetine was initiated and maintained at a dose of 4 mg/day.
A significant decrease in ADHD symptoms, on all scales measured, was noted. Adverse effects were relatively mild and transient. The most common adverse effects were drowsiness/sedation and gastrointestinal complaints.
The results of the current open-label study suggest the effectiveness of reboxetine in the treatment of ADHD in methylphenidate-resistant children and adolescents. Double-blind, placebo-, and active comparator-controlled studies are indicated to rigorously test the efficacy of reboxetine in ADHD.</description><identifier>ISSN: 0890-8567</identifier><identifier>EISSN: 1527-5418</identifier><identifier>DOI: 10.1097/01.chi.0000155327.30017.8c</identifier><identifier>PMID: 15843764</identifier><identifier>CODEN: JAAPEE</identifier><language>eng</language><publisher>Hagerstown, MD: Elsevier Inc</publisher><subject>Adolescent ; Adolescents ; Adrenergic Uptake Inhibitors - administration & dosage ; Adrenergic Uptake Inhibitors - adverse effects ; Adrenergic Uptake Inhibitors - therapeutic use ; Adult and adolescent clinical studies ; Anxiety ; anxiety symptoms ; Attention Deficit and Disruptive Behavior Disorders - epidemiology ; Attention Deficit Disorder with Hyperactivity - diagnosis ; Attention Deficit Disorder with Hyperactivity - drug therapy ; Attention Deficit Disorder with Hyperactivity - epidemiology ; Attention Deficit Disorders ; Attention deficit hyperactivity disorder ; Biological and medical sciences ; Child ; Clinical trials ; Depression ; Depression (Psychology) ; depressive symptoms ; Diagnostic and Statistical Manual of Mental Disorders ; Double-Blind Method ; Drug therapy ; Effectiveness studies ; Female ; Humans ; Hyperactivity ; Inhibitor drugs ; Male ; Manifest Anxiety Scale ; Medical sciences ; Mental depression ; Mood disorders ; Morpholines - administration & dosage ; Morpholines - adverse effects ; Morpholines - therapeutic use ; Neuropharmacology ; Pediatrics ; Pharmacology. Drug treatments ; Program Effectiveness ; Psychiatry ; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) ; Psychology. Psychoanalysis. Psychiatry ; Psychopathology. Psychiatry ; Psychopharmacology ; Rating Scales ; reboxetine</subject><ispartof>Journal of the American Academy of Child and Adolescent Psychiatry, 2005-05, Vol.44 (5), p.428-433</ispartof><rights>2005 The American Academy of Child and Adolescent Psychiatry</rights><rights>2005 INIST-CNRS</rights><rights>Copyright Lippincott Williams & Wilkins May 2005</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c456t-c8001d04df4d9d32fcb36edf221a62d63eaeeab40cdb63a5d190cf8b6d816c333</citedby><cites>FETCH-LOGICAL-c456t-c8001d04df4d9d32fcb36edf221a62d63eaeeab40cdb63a5d190cf8b6d816c333</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1097/01.chi.0000155327.30017.8c$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,777,781,3537,27905,27906,30980,45976</link.rule.ids><backlink>$$Uhttp://eric.ed.gov/ERICWebPortal/detail?accno=EJ697113$$DView record in ERIC$$Hfree_for_read</backlink><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16721211$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15843764$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ratner, Sharon</creatorcontrib><creatorcontrib>Laor, Nathaniel</creatorcontrib><creatorcontrib>Bronstein, Yifat</creatorcontrib><creatorcontrib>Weizman, Abraham</creatorcontrib><creatorcontrib>Toren, Paz</creatorcontrib><title>Six-Week Open-Label Reboxetine Treatment in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder</title><title>Journal of the American Academy of Child and Adolescent Psychiatry</title><addtitle>J Am Acad Child Adolesc Psychiatry</addtitle><description>This open-label study assessed the effectiveness of reboxetine, a selective norepinephrine reuptake inhibitor, in children and adolescents with attention-deficit/hyperactivity disorder (ADHD) resistant to a previous methylphenidate trial.
Thirty-one child and adolescent outpatients, aged 8 to 18 (mean age, 11.7; SD = 2.87) years, diagnosed with ADHD were enrolled in a 6-week open-label study. Assessments included rater-administered scales (DSM-IV ADHD Scale; Clinical Global Impressions Scale), parent-administered scales (the Abbreviated Conners Rating Scale), and self-administered-scales for the evaluation of depressive (Children's Depression Inventory) and anxiety (the Revised Children's Manifest Anxiety Scale) symptoms. Reboxetine was initiated and maintained at a dose of 4 mg/day.
A significant decrease in ADHD symptoms, on all scales measured, was noted. Adverse effects were relatively mild and transient. The most common adverse effects were drowsiness/sedation and gastrointestinal complaints.
The results of the current open-label study suggest the effectiveness of reboxetine in the treatment of ADHD in methylphenidate-resistant children and adolescents. Double-blind, placebo-, and active comparator-controlled studies are indicated to rigorously test the efficacy of reboxetine in ADHD.</description><subject>Adolescent</subject><subject>Adolescents</subject><subject>Adrenergic Uptake Inhibitors - administration & dosage</subject><subject>Adrenergic Uptake Inhibitors - adverse effects</subject><subject>Adrenergic Uptake Inhibitors - therapeutic use</subject><subject>Adult and adolescent clinical studies</subject><subject>Anxiety</subject><subject>anxiety symptoms</subject><subject>Attention Deficit and Disruptive Behavior Disorders - epidemiology</subject><subject>Attention Deficit Disorder with Hyperactivity - diagnosis</subject><subject>Attention Deficit Disorder with Hyperactivity - drug therapy</subject><subject>Attention Deficit Disorder with Hyperactivity - epidemiology</subject><subject>Attention Deficit Disorders</subject><subject>Attention deficit hyperactivity disorder</subject><subject>Biological and medical sciences</subject><subject>Child</subject><subject>Clinical trials</subject><subject>Depression</subject><subject>Depression (Psychology)</subject><subject>depressive symptoms</subject><subject>Diagnostic and Statistical Manual of Mental Disorders</subject><subject>Double-Blind Method</subject><subject>Drug therapy</subject><subject>Effectiveness studies</subject><subject>Female</subject><subject>Humans</subject><subject>Hyperactivity</subject><subject>Inhibitor drugs</subject><subject>Male</subject><subject>Manifest Anxiety Scale</subject><subject>Medical sciences</subject><subject>Mental depression</subject><subject>Mood disorders</subject><subject>Morpholines - administration & dosage</subject><subject>Morpholines - adverse effects</subject><subject>Morpholines - therapeutic use</subject><subject>Neuropharmacology</subject><subject>Pediatrics</subject><subject>Pharmacology. Drug treatments</subject><subject>Program Effectiveness</subject><subject>Psychiatry</subject><subject>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopathology. Psychiatry</subject><subject>Psychopharmacology</subject><subject>Rating Scales</subject><subject>reboxetine</subject><issn>0890-8567</issn><issn>1527-5418</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>7QJ</sourceid><recordid>eNqNkF1v0zAUhi0EYmXwDxCyJnGZzI4Tx-WuagcDVZoEQ7u0nOMT1SN1iu1O67_HpRG9xTe29T7nQw8hV5yVnM3ba8ZL2LiS5cObRlRtKfKrLRW8IDPeVG3R1Fy9JDOm5qxQjWwvyJsYH498q9RrcsEbVYtW1jMSfrjn4gHxF73boS_WpsOBfsdufMbkPNL7gCZt0SfqPF1u3GADemq8pQs7DhghR5E-uLShi5Tyx42-WGHvwKXr28MOg4Hknlw60JWLY7AY3pJXvRkivpvuS_Lz88398rZY3335ulysC6gbmQpQeV3LatvXdm5F1UMnJNq-qriRlZUCDaLpaga2k8I0ls8Z9KqTVnEJQohLcnXquwvj7z3GpB_HffB5pK54JWtZsyP06QRBGGMM2OtdcFsTDpozfbStGdfZtj7b1n9tawW5-MM0Yd9t0Z5LJ70Z-DgBJoIZ-mA8uHjmZJs34Txz708cBgf_4ptvct7mNMerKc66nhwGHcGhB7QuICRtR_c_6_4BXTip3Q</recordid><startdate>20050501</startdate><enddate>20050501</enddate><creator>Ratner, Sharon</creator><creator>Laor, Nathaniel</creator><creator>Bronstein, Yifat</creator><creator>Weizman, Abraham</creator><creator>Toren, Paz</creator><general>Elsevier Inc</general><general>Lippincott Williams & Wilkins</general><general>Lippincott</general><general>Elsevier BV</general><scope>7SW</scope><scope>BJH</scope><scope>BNH</scope><scope>BNI</scope><scope>BNJ</scope><scope>BNO</scope><scope>ERI</scope><scope>PET</scope><scope>REK</scope><scope>WWN</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QJ</scope><scope>7TK</scope><scope>K9.</scope></search><sort><creationdate>20050501</creationdate><title>Six-Week Open-Label Reboxetine Treatment in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder</title><author>Ratner, Sharon ; Laor, Nathaniel ; Bronstein, Yifat ; Weizman, Abraham ; Toren, Paz</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c456t-c8001d04df4d9d32fcb36edf221a62d63eaeeab40cdb63a5d190cf8b6d816c333</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Adolescent</topic><topic>Adolescents</topic><topic>Adrenergic Uptake Inhibitors - administration & dosage</topic><topic>Adrenergic Uptake Inhibitors - adverse effects</topic><topic>Adrenergic Uptake Inhibitors - therapeutic use</topic><topic>Adult and adolescent clinical studies</topic><topic>Anxiety</topic><topic>anxiety symptoms</topic><topic>Attention Deficit and Disruptive Behavior Disorders - epidemiology</topic><topic>Attention Deficit Disorder with Hyperactivity - diagnosis</topic><topic>Attention Deficit Disorder with Hyperactivity - drug therapy</topic><topic>Attention Deficit Disorder with Hyperactivity - epidemiology</topic><topic>Attention Deficit Disorders</topic><topic>Attention deficit hyperactivity disorder</topic><topic>Biological and medical sciences</topic><topic>Child</topic><topic>Clinical trials</topic><topic>Depression</topic><topic>Depression (Psychology)</topic><topic>depressive symptoms</topic><topic>Diagnostic and Statistical Manual of Mental Disorders</topic><topic>Double-Blind Method</topic><topic>Drug therapy</topic><topic>Effectiveness studies</topic><topic>Female</topic><topic>Humans</topic><topic>Hyperactivity</topic><topic>Inhibitor drugs</topic><topic>Male</topic><topic>Manifest Anxiety Scale</topic><topic>Medical sciences</topic><topic>Mental depression</topic><topic>Mood disorders</topic><topic>Morpholines - administration & dosage</topic><topic>Morpholines - adverse effects</topic><topic>Morpholines - therapeutic use</topic><topic>Neuropharmacology</topic><topic>Pediatrics</topic><topic>Pharmacology. Drug treatments</topic><topic>Program Effectiveness</topic><topic>Psychiatry</topic><topic>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopathology. Psychiatry</topic><topic>Psychopharmacology</topic><topic>Rating Scales</topic><topic>reboxetine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ratner, Sharon</creatorcontrib><creatorcontrib>Laor, Nathaniel</creatorcontrib><creatorcontrib>Bronstein, Yifat</creatorcontrib><creatorcontrib>Weizman, Abraham</creatorcontrib><creatorcontrib>Toren, Paz</creatorcontrib><collection>ERIC</collection><collection>ERIC (Ovid)</collection><collection>ERIC</collection><collection>ERIC</collection><collection>ERIC (Legacy Platform)</collection><collection>ERIC( SilverPlatter )</collection><collection>ERIC</collection><collection>ERIC PlusText (Legacy Platform)</collection><collection>Education Resources Information Center (ERIC)</collection><collection>ERIC</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Applied Social Sciences Index & Abstracts (ASSIA)</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><jtitle>Journal of the American Academy of Child and Adolescent Psychiatry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ratner, Sharon</au><au>Laor, Nathaniel</au><au>Bronstein, Yifat</au><au>Weizman, Abraham</au><au>Toren, Paz</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><ericid>EJ697113</ericid><atitle>Six-Week Open-Label Reboxetine Treatment in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder</atitle><jtitle>Journal of the American Academy of Child and Adolescent Psychiatry</jtitle><addtitle>J Am Acad Child Adolesc Psychiatry</addtitle><date>2005-05-01</date><risdate>2005</risdate><volume>44</volume><issue>5</issue><spage>428</spage><epage>433</epage><pages>428-433</pages><issn>0890-8567</issn><eissn>1527-5418</eissn><coden>JAAPEE</coden><abstract>This open-label study assessed the effectiveness of reboxetine, a selective norepinephrine reuptake inhibitor, in children and adolescents with attention-deficit/hyperactivity disorder (ADHD) resistant to a previous methylphenidate trial.
Thirty-one child and adolescent outpatients, aged 8 to 18 (mean age, 11.7; SD = 2.87) years, diagnosed with ADHD were enrolled in a 6-week open-label study. Assessments included rater-administered scales (DSM-IV ADHD Scale; Clinical Global Impressions Scale), parent-administered scales (the Abbreviated Conners Rating Scale), and self-administered-scales for the evaluation of depressive (Children's Depression Inventory) and anxiety (the Revised Children's Manifest Anxiety Scale) symptoms. Reboxetine was initiated and maintained at a dose of 4 mg/day.
A significant decrease in ADHD symptoms, on all scales measured, was noted. Adverse effects were relatively mild and transient. The most common adverse effects were drowsiness/sedation and gastrointestinal complaints.
The results of the current open-label study suggest the effectiveness of reboxetine in the treatment of ADHD in methylphenidate-resistant children and adolescents. Double-blind, placebo-, and active comparator-controlled studies are indicated to rigorously test the efficacy of reboxetine in ADHD.</abstract><cop>Hagerstown, MD</cop><pub>Elsevier Inc</pub><pmid>15843764</pmid><doi>10.1097/01.chi.0000155327.30017.8c</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0890-8567 |
| ispartof | Journal of the American Academy of Child and Adolescent Psychiatry, 2005-05, Vol.44 (5), p.428-433 |
| issn | 0890-8567 1527-5418 |
| language | eng |
| recordid | cdi_proquest_journals_212646403 |
| source | MEDLINE; Elsevier ScienceDirect Journals; Applied Social Sciences Index & Abstracts (ASSIA) |
| subjects | Adolescent Adolescents Adrenergic Uptake Inhibitors - administration & dosage Adrenergic Uptake Inhibitors - adverse effects Adrenergic Uptake Inhibitors - therapeutic use Adult and adolescent clinical studies Anxiety anxiety symptoms Attention Deficit and Disruptive Behavior Disorders - epidemiology Attention Deficit Disorder with Hyperactivity - diagnosis Attention Deficit Disorder with Hyperactivity - drug therapy Attention Deficit Disorder with Hyperactivity - epidemiology Attention Deficit Disorders Attention deficit hyperactivity disorder Biological and medical sciences Child Clinical trials Depression Depression (Psychology) depressive symptoms Diagnostic and Statistical Manual of Mental Disorders Double-Blind Method Drug therapy Effectiveness studies Female Humans Hyperactivity Inhibitor drugs Male Manifest Anxiety Scale Medical sciences Mental depression Mood disorders Morpholines - administration & dosage Morpholines - adverse effects Morpholines - therapeutic use Neuropharmacology Pediatrics Pharmacology. Drug treatments Program Effectiveness Psychiatry Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) Psychology. Psychoanalysis. Psychiatry Psychopathology. Psychiatry Psychopharmacology Rating Scales reboxetine |
| title | Six-Week Open-Label Reboxetine Treatment in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T16%3A12%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Six-Week%20Open-Label%20Reboxetine%20Treatment%20in%20Children%20and%20Adolescents%20With%20Attention-Deficit/Hyperactivity%20Disorder&rft.jtitle=Journal%20of%20the%20American%20Academy%20of%20Child%20and%20Adolescent%20Psychiatry&rft.au=Ratner,%20Sharon&rft.date=2005-05-01&rft.volume=44&rft.issue=5&rft.spage=428&rft.epage=433&rft.pages=428-433&rft.issn=0890-8567&rft.eissn=1527-5418&rft.coden=JAAPEE&rft_id=info:doi/10.1097/01.chi.0000155327.30017.8c&rft_dat=%3Cproquest_cross%3E829312411%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=212646403&rft_id=info:pmid/15843764&rft_ericid=EJ697113&rft_els_id=S0890856709615033&rfr_iscdi=true |